Seven months after launching with $16 million in seed financing, Jennifer Doudna’s Aurora Therapeutics is pivoting away from its lead indication, phenylketonuria, owing to growing competition in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results